Co-Inventors
Edwin Ades (CDC)
George Carlone (CDC)
Jacquelyn Sampson (CDC)
Development Status
- Pre-clinical
- In vitro data available
- In vivo data available (animal)
This invention relates to synthetic immunoreactive peptides, which are portions of the M proteins of the most prevalent Group A Streptococcus (GAS) serotypes in the United States. These peptides may be useful in development of a flexible, multivalent GAS vaccine. They can be recognized by M type-specific antibodies and are capable of eliciting functional opsonic antibodies. Additionally, the peptides or isolated antibodies raised in response to the peptides may be useful for GAS diagnostics.
Commercial Applications
- Group A streptococci (GAS) vaccine
- GAS therapeutics and diagnostics
- Lab tools for exploring GAS
Competitive Advantages
- Easily adaptable to kit form
- Multivalent vaccine that can be tailored for protection against specific GAS serotypes affecting a particular population